A Free Educational Webinar for Melanoma Patients and CaregiversThursday, October 16 | 7:00–7:30 PM ET Facing melanoma can be overwhelming—especially when initial treatment doesn’t go as hoped. If you’ve recently learned that your first-line therapy has stopped working, or you’re supporting someone who has, you may be wondering what comes next. Our upcoming live webinar, “I’ve Failed First-Line Therapy – ... Read More| AIM at Melanoma Foundation
Focus on TIGIT Immunotherapy What Is Immunotherapy? Many people with healthy immune systems still develop cancer. Sometimes the immune system doesn’t see the cancer cells as foreign because the cells aren’t different enough from normal cells, and sometimes the immune system recognizes the cancer cells, but the response might not be strong enough to destroy the cancer. Immunotherapy is a treatment approach ... Read More The post New Advances in Phase 3 Treatments for Melanoma appeared fi...| AIM at Melanoma Foundation
FDA Rejects Promising Melanoma Treatment On July 22, 2025, the Food and Drug Administration (FDA) rejected the approval of a treatment for advanced melanoma that had shown promise in clinical trials. RP1 (vusolimogene oderparepvec) is an oncolytic immunotherapy given in combination with nivolumab (Opdivo). RP1 + nivolumab would have been a second-line treatment for patients with advanced melanoma that did ... Read More| AIM at Melanoma Foundation
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT) today announces topline results from the pivotal Phase 3 trial of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio® (imsapepimut and etimupepimut, adjuvanted). The trial evaluated Cylembio in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), vs. pembrolizumab alone as a first-line treatment in 407 patients with unresectable or metastatic (advanced) ... Re...| AIM at Melanoma Foundation
